Arrayit Diagnostics signs special License Agreement with Wayne State University Arrayit Diagnostics, Inc., a majority-possessed subsidiary of Arrayit Corporation , today announced that it has signed an exclusive License Contract with Wayne State University to key intellectual property covering discoveries of biomarkers of ovarian cancer tumor. The agreement with Wayne State University grants Arrayit unique worldwide rights to develop and commercialize a novel microarray-based diagnostic test using biomarkers developed by Professors Michael Tainsky of the School of Medicine and Sorin Draghici of the College of Liberal Arts and Sciences, and Madhumita Chatterjee, research associate in the institution of Medicine colchicine-vs-naproxen.htm .
Array BioPharma to provide data on ARRY-520 Phase 1 trial for multiple myeloma in ASH Annual Meeting Array BioPharma Inc. today announced that it’ll present data from a Phase 1 trial of KSP inhibitor ARRY-520 in individuals with relapsed/refractory multiple myeloma at the 2010 Annual Meeting of the American Culture of Hematology in Orlando, Florida on Saturday, December 4, 2010. The abstract could be accessed through the ASH website, The abstract name is provided below, however, please be aware that relating to ASH policy, all data is definitely embargoed until the time of the start of the presentation. The poster will be accessible as a PDF after it really is presented on Array’s website at..